RADIUS HEALTH, INC. (NASDAQ:RDUS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective May 25, 2018, Gregory C. Williams, Ph.D., MBA, will transition to a consulting relationship with Radius Health, Inc, (the “Company”) until up to March 31, 2019. During this period, Dr. Williams has agreed to provide consulting services to the Company, on an as-needed basis, for up to 60 hours per month. In addition to the separation benefits provided for to his executive severance agreement with the Company dated July 1, 2015, Dr. Williams is entitled to receive a lump sum bonus of $100,000 in January 2019.
About RADIUS HEALTH, INC. (NASDAQ:RDUS)
Radius Health, Inc. is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.
